<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39439862</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1661-3791</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Breast care (Basel, Switzerland)</Title><ISOAbbreviation>Breast Care (Basel)</ISOAbbreviation></Journal><ArticleTitle>Retrospective Impact of COVID-19 Pandemic on Primary Breast Cancer Care.</ArticleTitle><Pagination><StartPage>270</StartPage><EndPage>281</EndPage><MedlinePgn>270-281</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000541015</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The COVID-19 pandemic has transformed breast cancer care for patients and healthcare providers. Circumstances varied greatly by region and hospital, depending on COVID-19 prevalence, case mix, hospital type, and available resources. These challenges have disrupted screening programs and have been particularly distressing for both women with a breast cancer diagnosis and their providers.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="UNASSIGNED">This review explores the retrospective impact of the COVID-19 pandemic on primary breast cancer care. It analyzes changes in screening participation, diagnosis rates, treatment modalities, and the delivery of psycho-oncological support during the pandemic. The study found a significant reduction in breast cancer screenings and a subsequent stage shift in diagnoses, with fewer early-stage and more advanced-stage cancers being detected. Additionally, the review discusses the psychosocial challenges faced by patients and the adaptations made in care delivery, such as the increased use of telemedicine. Despite these challenges, the healthcare systems showed resilience, with core treatment services largely maintained and rapid adaptations to new care models.</AbstractText><AbstractText Label="KEY MESSAGES" NlmCategory="UNASSIGNED">There was a marked decrease in breast cancer screenings and early diagnoses during the pandemic, with a shift toward more advanced-stage detections. While there was an increased use of neoadjuvant therapies and telemedicine, essential breast cancer treatments were mostly sustained, reflecting the resilience of healthcare systems. The pandemic significantly impacted the mental health of breast cancer patients, exacerbating anxiety and depression and highlighting the need for improved psycho-oncological support. The full impact of these disruptions on long-term breast cancer outcomes remains uncertain, necessitating ongoing monitoring and adaptation of care strategies to mitigate adverse effects.</AbstractText><CopyrightInformation>© 2024 The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pruss</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neubacher</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dietzel</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, Medical Faculty, University Düsseldorf, Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krawczyk</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cieslik</LastName><ForeName>Jan-Philipp</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohrmann</LastName><ForeName>Svjetlana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruckhäberle</LastName><ForeName>Eugen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturm-Inwald</LastName><ForeName>Elisabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fehm</LastName><ForeName>Tanja N</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behrens</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Breast Care (Basel)</MedlineTA><NlmUniqueID>101254060</NlmUniqueID><ISSNLinking>1661-3791</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast cancer care</Keyword><Keyword MajorTopicYN="N">COVID-19 pandemic</Keyword><Keyword MajorTopicYN="N">Cancer screening disruptions</Keyword><Keyword MajorTopicYN="N">Psychological impacts</Keyword><Keyword MajorTopicYN="N">Treatment approaches</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest related to this research. There are no financial, personal, or professional relationships that could be construed as influencing the work reported in this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39439862</ArticleId><ArticleId IdType="pmc">PMC11493392</ArticleId><ArticleId IdType="doi">10.1159/000541015</ArticleId><ArticleId IdType="pii">541015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li T, Nickel B, Ngo P, McFadden K, Brennan M, Marinovich ML, et al. . A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis. Breast. 2023;67:78–88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9813855</ArticleId><ArticleId IdType="pubmed">36646004</ArticleId></ArticleIdList></Reference><Reference><Citation>Teglia F, Angelini M, Casolari G, Astolfi L, Boffetta P. Global association of COVID-19 pandemic measures with cancer treatment: a systematic review and meta-analysis. Cancers. 2022;14(22):5490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9688091</ArticleId><ArticleId IdType="pubmed">36428583</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibold A, Papatla K, Zeligs KP, Blank SV. COVID-19 and gynecologic oncology: what have we learned? Curr Treat Options Oncol. 2021;22(12):117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609172</ArticleId><ArticleId IdType="pubmed">34812973</ArticleId></ArticleIdList></Reference><Reference><Citation>Fröhling S, Volker A, Baumann M. Corona-Effekt in der Onkologie. Deutsches Ärzteblatt. 2020;Jg 117(Heft 46).</Citation></Reference><Reference><Citation>Arndt V, Doege D, Fröhling S, Albers P, Algül H, Bargou R, et al. . Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic. J Cancer Res Clin Oncol. 2023;149(2):913–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9568964</ArticleId><ArticleId IdType="pubmed">36241862</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Yang NN, Nogueira L, Jiang C, Wagle NS, Zhao J, et al. . Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional Nationwide assessment. Lancet Oncol. 2023;24(8):855–67.</Citation><ArticleIdList><ArticleId IdType="pubmed">37541271</ArticleId></ArticleIdList></Reference><Reference><Citation>Kripalani S, Kulshreshta S, Saracco B, Meterissian S. The effect of COVID-19 on breast cancer care and treatment in North America: a scoping review. Am J Surg. 2022;224(5):1222–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9347185</ArticleId><ArticleId IdType="pubmed">35945067</ArticleId></ArticleIdList></Reference><Reference><Citation>Teglia F, Angelini M, Astolfi L, Casolari G, Boffetta P. Global association of COVID-19 pandemic measures with cancer screening: a systematic review and meta-analysis. JAMA Oncol. 2022;8(9):1287–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9264214</ArticleId><ArticleId IdType="pubmed">35797056</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero LR, Wallace SP. The impact of COVID-19 on diverse older adults and health equity in the United States. Front Public Health. 2021;9:661592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8165264</ArticleId><ArticleId IdType="pubmed">34079786</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm LJ, Lee C, Rosenberg RD, Burleson J, Simanowith M, Fruscello T Jr, et al. . Impact of the COVID-19 pandemic on breast imaging: an analysis of the National mammography database. J Am Coll Radiol. 2022;19(8):919–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9174535</ArticleId><ArticleId IdType="pubmed">35690079</ArticleId></ArticleIdList></Reference><Reference><Citation>DeGroff A, Miller J, Sharma K, Sun J, Helsel W, Kammerer W, et al. . COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program, January-June 2020, in the United States. Prev Med. 2021;151:106559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9026719</ArticleId><ArticleId IdType="pubmed">34217410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mani SS, Schut RA. The impact of the COVID-19 pandemic on inequalities in preventive health screenings: trends and implications for U.S. population health. Soc Sci Med. 2023;328:116003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10238126</ArticleId><ArticleId IdType="pubmed">37301108</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mast C, Munoz A, Heist T. Cancers screenings are still lagging Epic Health Research Network, 2021. [Online]. Available from: https://epicresearchblob.blob.core.windows.net/cms-uploads/pdfs/cancer-screenings-are-still-lagging.pdf</Citation></Reference><Reference><Citation>Elek P, Fadgyas-Freyler P, Varadi B, Mayer B, Zemplenyi A, Csanadi M. Effects of lower screening activity during the COVID-19 pandemic on breast cancer patient pathways: evidence from the age cut-off of organized screening. Health Pol. 2022;126(8):763–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9130317</ArticleId><ArticleId IdType="pubmed">35690504</ArticleId></ArticleIdList></Reference><Reference><Citation>Starker A, Kraywinkel K, Kuhnert R. Early detection of breast cancer: the utilization of mammography in Germany. J Health Monit. 2017;2(4):69–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10165918</ArticleId><ArticleId IdType="pubmed">37168129</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mangiapane S, Kretschmann J, Czihal T, von Stillfried D. Veränderung der vertragsaarztlichen Leistungsinanspruchnahme während der COVID-Krise. Zentralinstitut für die kassenärztliche Versorgung Deutschland. 2022. [Online]. Available from: https://www.zi.de/fileadmin/Downloads/Service/Publikationen/Trendreport_7_Leistungsinanspruchnahme_COVID_2022-12-08.pdf</Citation></Reference><Reference><Citation>
Tillmanns H, Schillinger G, Drather H. “Inanspruchnahme von Fruherkennungsleistungen der gesetzlichen Krankenversicherung durch AOK-Versicherte im Erwachsenenalter 2007 bis 2021”. Wissenschaftliches Institut der AOK (WIdO); 2022. [Online]. Available from: https://www.wido.de/fileadmin/Dateien/Bilder/Forschung_Projekte/Ambulante_Versorgung/Frueherkennung_bei_Erwachsenen_2007_2021.pdf</Citation></Reference><Reference><Citation>Fedewa SA, Star J, Bandi P, Minihan A, Han X, Yabroff KR, et al. . Changes in cancer screening in the US during the COVID-19 pandemic. JAMA Netw Open. 2022;5(6):e2215490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9166223</ArticleId><ArticleId IdType="pubmed">35657622</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinmohamed AG, Cellamare M, Visser O, de Munck L, Elferink MAG, Westenend PJ, et al. . The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in The Netherlands. J Hematol Oncol. 2020;13(1):147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7609826</ArticleId><ArticleId IdType="pubmed">33148289</ArticleId></ArticleIdList></Reference><Reference><Citation>
Krebsregister schleswig-holstein. [Online]. Available from: https://www.krebsregister-sh.de/iWOB/index.html#/database/timeline</Citation></Reference><Reference><Citation>
Krebsregister Hamburg. [Online]. Available from: https://interaktiverbericht.krebsregister-hamburg.de/#/diagnoses/overview</Citation></Reference><Reference><Citation>
Krebsregister thüringen. [Online]. Available from: https://cloud.krebsregister-thueringen.de/owncloud/index.php/s/1BKyMoBMP6o3ldm</Citation></Reference><Reference><Citation>Minucci A, Scambia G, De Bonis M, De Paolis E, Santonocito C, Fagotti A, et al. . BRCA testing delay during the COVID-19 pandemic: how to act? Mol Biol Rep. 2021;48(1):983–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7733534</ArticleId><ArticleId IdType="pubmed">33313973</ArticleId></ArticleIdList></Reference><Reference><Citation>Benusiglio PR, Korenbaum C, Vibert R, Ezenfis J, Geoffron S, Paul C, et al. . Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic. Eur J Med Genet. 2020;63(12):104098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654320</ArticleId><ArticleId IdType="pubmed">33186762</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsibulak I, Reiser E, Bogner G, Petru E, Hell-Teutsch J, Reinthaller A, et al. . Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective. Int J Gynecol Cancer. 2020;30(11):1667–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7656153</ArticleId><ArticleId IdType="pubmed">33033166</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng JS, Hamilton DG. Assessing the impact of the COVID-19 pandemic on breast cancer screening and diagnosis rates: a rapid review and meta-analysis. J Med Screen. 2022;29(4):209–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127453</ArticleId><ArticleId IdType="pubmed">35593115</ArticleId></ArticleIdList></Reference><Reference><Citation>Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. . Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21(8):1035–44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116538</ArticleId><ArticleId IdType="pubmed">32702311</ArticleId></ArticleIdList></Reference><Reference><Citation>Toss A, Callegari V, Cortesi G, Civallero M, Armocida C, Piacentini F. COVID-related disruption in mammographic screening: a year later. ESMO Open. 2022;7(4):100539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9278125</ArticleId><ArticleId IdType="pubmed">35841805</ArticleId></ArticleIdList></Reference><Reference><Citation>Linck PA, Garnier C, Depetiteville MP, MacGrogan G, Mathoulin-Pélissier S, Quénel-Tueux N, et al. . Impact of the COVID-19 lockdown in France on the diagnosis and staging of breast cancers in a tertiary cancer centre. Eur Radiol. 2022;32(3):1644–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8514205</ArticleId><ArticleId IdType="pubmed">34647179</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckford RD, Gaisser A, Arndt V, Baumann M, Kludt E, Mehlis K, et al. . The COVID-19 pandemic and cancer patients in Germany: impact on treatment, follow-up care and psychological burden. Front Public Health. 2021;9:788598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865576</ArticleId><ArticleId IdType="pubmed">35223757</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano EC, Perndorfer C, Otto AK, Fenech AL, Siegel SD, Dickson-Witmer D, et al. . Psychosocial impact of cancer care disruptions in women with breast cancer during the COVID-19 pandemic. Front Psychol. 2021;12:662339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8236578</ArticleId><ArticleId IdType="pubmed">34194367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallay E, Medrea F, Degi CL. On top of that all, now Covid-19, too. A scoping review of specificities and correlates of fear of cancer recurrence in breast cancer patients during COVID-19. Breast. 2022;62:123–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828428</ArticleId><ArticleId IdType="pubmed">35176683</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandinelli L, Ornell F, von Diemen L, Kessler FHP. The sum of fears in cancer patients inside the context of the COVID-19. Front Psychiatry. 2021;12:557834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058213</ArticleId><ArticleId IdType="pubmed">33897477</ArticleId></ArticleIdList></Reference><Reference><Citation>de Joode K, Dumoulin DW, Tol J, Westgeest HM, Beerepoot LV, van den Berkmortel FWPJ, et al. . Dutch Oncology COVID-19 consortium: outcome of COVID-19 in patients with cancer in a Nationwide cohort study. Eur J Cancer. 2020;141:171–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7540213</ArticleId><ArticleId IdType="pubmed">33161241</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigorski D, Sobczuk P, Osmola M, Kuć K, Walerzak A, Wilk M, et al. . Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy. ESMO Open. 2020;5(5):e000970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590347</ArticleId><ArticleId IdType="pubmed">33097653</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab R, Droste A, Stewen K, Brenner W, Schmidt M, Hasenburg A. Patients’ expectations of preventive measures of medical institutions during the SARS-CoV-2 pandemic in Germany in women with an increased risk of breast and ovarian cancer: a cross-sectional, web-based survey. BMJ Open. 2022;12(5):e060038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9096054</ArticleId><ArticleId IdType="pubmed">35545389</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab R, Droste A, Stewen K, Elger T, Theis S, Heimes AS, et al. . Resilience as a source of easement to health-related worries in women at increased risk for breast or ovarian cancer during the COVID-19 pandemic. Int J Gen Med. 2022;15:7039–52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9462434</ArticleId><ArticleId IdType="pubmed">36090707</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Liu X, Tong F, Zhou R, Peng W, Yang H, et al. . The prevalence of psychological disorders among cancer patients during the COVID-19 pandemic: a meta-analysis. Psychooncology. 2022;31(11):1972–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538248</ArticleId><ArticleId IdType="pubmed">35950545</ArticleId></ArticleIdList></Reference><Reference><Citation>Eijkelboom AH, de Munck L, Menke-van der Houven van Oordt CW, Broeders MJM, van den Bongard DHJG, Strobbe LJA, et al. . Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study. Breast Cancer Res Treat. 2023;197(1):161–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9638417</ArticleId><ArticleId IdType="pubmed">36334188</ArticleId></ArticleIdList></Reference><Reference><Citation>Fader AN, Huh WK, Kesterson J, Pothuri B, Wethington S, Wright JD, et al. . When to operate, hesitate and reintegrate: society of gynecologic oncology surgical considerations during the COVID-19 pandemic. Gynecol Oncol. 2020;158(2):236–43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275160</ArticleId><ArticleId IdType="pubmed">32532460</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns A, Jones VM, Cronin K, Yocobozzi M, Howard C, Lesko N, et al. . Impact of the COVID-19 pandemic on breast cancer screening and operative treatment. Am Surg. 2022;88(6):1051–3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014363</ArticleId><ArticleId IdType="pubmed">35417262</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaisser A, Eckford RD, Arndt V, Doege D, Kludt E, Ubels J, et al. . [Nearly two years of the coronavirus pandemic from the perspective of people affected by cancer]. Onkologe. 2022;28(3):248–52. Fast zwei Jahre Coronapandemie aus der Perspektive von Krebsbetroffenen.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8796180</ArticleId><ArticleId IdType="pubmed">35106030</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasbey J, Ademuyiwa A, Adisa A, AlAmeer E, Arnaud AP, Ayasra F, et al. . Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an International, prospective, cohort study. Lancet Oncol. 2021;22(11):1507–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492020</ArticleId><ArticleId IdType="pubmed">34624250</ArticleId></ArticleIdList></Reference><Reference><Citation>
Gunster C. WIdO-Report: Entwicklung der Krankenhausfallzahlen wahrend des Coronavirus-Lockdowns. Wissenschaftlichen Institut der AOK (WldO); 2020. [Online]. Available from: https://www.wido.de/fileadmin/Dateien/Bilder/News/2020_06_WIdO-Report_FZ-Entwicklung_Lockdown.pdf</Citation></Reference><Reference><Citation>de Bock E, Herman ES, Bastian OW, Filipe MD, Vriens MR, Richir MC. Systematic review and meta-analysis determining the effect of implemented COVID-19 guidelines on surgical oncology volumes and clinical outcomes. Surg Oncol. 2022;45:101859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9529677</ArticleId><ArticleId IdType="pubmed">36242979</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadili L, DeGirolamo K, McKevitt E, Brown CJ, Prabhakar C, Pao JS, et al. . COVID-19 and breast cancer at a Regional Breast Centre: our flexible approach during the pandemic. Breast Cancer Res Treat. 2021;186(2):519–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7640574</ArticleId><ArticleId IdType="pubmed">33146785</ArticleId></ArticleIdList></Reference><Reference><Citation>Fancellu A, Sanna V, Rubino C, Ariu ML, Piredda C, Piana GQ, et al. . The COVID-19 outbreak may Be associated to a reduced level of care for breast cancer. A comparative study with the pre-COVID era in an Italian breast unit. Healthc. 2020;8(4):474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7712282</ArticleId><ArticleId IdType="pubmed">33187343</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanni G, Pellicciaro M, Materazzo M, Dauri M, D’angelillo RM, Buonomo C, et al. . Awake breast cancer surgery: strategy in the beginning of COVID-19 emergency. Breast Cancer. 2021;28(1):137–44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391474</ArticleId><ArticleId IdType="pubmed">32734327</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanni G, Tazzioli G, Pellicciaro M, Materazzo M, Paolo O, Cattadori F, et al. . Delay in breast cancer treatments during the first COVID-19 lockdown. A multicentric analysis of 432 patients. Anticancer Res. 2020;40(12):7119–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33288611</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathelin C, Ame S, Anyanwu S, Avisar E, Boubnider WM, Breitling K, et al. . Breast cancer management during the COVID-19 pandemic: the senologic International Society survey. Eur J Breast Health. 2021;17(2):188–96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8025718</ArticleId><ArticleId IdType="pubmed">33870120</ArticleId></ArticleIdList></Reference><Reference><Citation>ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer, ESMO. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7295852</ArticleId><ArticleId IdType="pubmed">32439716</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenstein RN, Stern CS, Plotsker EL, Haglich K, Tadros AB, Mehrara BJ, et al. . Effects of COVID-19 on mastectomy and breast reconstruction rates: a national surgical sample. J Surg Oncol. 2022;126(2):205–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088456</ArticleId><ArticleId IdType="pubmed">35411946</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph WJ, Bustos SS, Losee JE, Rubin JP, de la Cruz C. The impact of the COVID-19 pandemic on breast reconstruction practices in the United States. Anticancer Res. 2021;41(4):1903–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33813395</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemal K, Boyd CJ, Bekisz JM, Salibian AA, Choi M, Karp NS. Breast reconstruction during the COVID-19 pandemic: a systematic review. Plast Reconstr Surg Glob Open. 2021;9(9):e3852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8460228</ArticleId><ArticleId IdType="pubmed">34584831</ArticleId></ArticleIdList></Reference><Reference><Citation>Caswell-Jin JL, Shafaee MN, Xiao L, Liu M, John EM, Bondy ML, et al. . Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population. Breast Cancer Res Treat. 2022;194(2):475–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9140322</ArticleId><ArticleId IdType="pubmed">35624175</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakouny Z, Labaki C, Bhalla S, Schmidt AL, Steinharter JA, Cocco J, et al. . Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study. Ann Oncol. 2022;33(8):836–44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197329</ArticleId><ArticleId IdType="pubmed">35715285</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger JM, Xiao H. The COVID-19 pandemic and new clinical trial activations. Trials. 2021;22(1):260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027975</ArticleId><ArticleId IdType="pubmed">33832534</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger JM. Cancer care during COVID-19-A shock to the system. JAMA Netw Open. 2022;5(4):e228864.</Citation><ArticleIdList><ArticleId IdType="pubmed">35467736</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleury ME, Farner AM, Unger JM. Association of the COVID-19 outbreak with patient willingness to enroll in cancer clinical trials. JAMA Oncol. 2021;7(1):131–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662493</ArticleId><ArticleId IdType="pubmed">33180102</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotopoulou C, Khan T, Bracinik J, Glasbey J, Abu-Rustum N, Chiva L, et al. . Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an International, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study. Am J Obstet Gynecol. 2022;227(5):735 e1–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9242690</ArticleId><ArticleId IdType="pubmed">35779589</ArticleId></ArticleIdList></Reference><Reference><Citation>Alagoz O, Lowry KP, Kurian AW, Mandelblatt JS, Ergun MA, Huang H, et al. . Impact of the COVID-19 pandemic on breast cancer mortality in the US: estimates from collaborative simulation modeling. J Natl Cancer Inst. 2021;113(11):1484–94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8344930</ArticleId><ArticleId IdType="pubmed">34258611</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Screening Working Group WG2 of the Covid-19 and Cancer Global Modelling Consortium, Figueroa JD, Gray E, Pashayan N, Deandrea S, Karch A, et al. . The impact of the Covid-19 pandemic on breast cancer early detection and screening. Prev Med. 2021;151:106585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241687</ArticleId><ArticleId IdType="pubmed">34217412</ArticleId></ArticleIdList></Reference><Reference><Citation>Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. . The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a National, population-based, modelling study. Lancet Oncol. 2020;21(8):1023–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417808</ArticleId><ArticleId IdType="pubmed">32702310</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong JH, Mainprize JG, Yaffe MJ, Ruan Y, Poirier AE, Coldman A, et al. . The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada. J Med Screen. 2021;28(2):100–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7691762</ArticleId><ArticleId IdType="pubmed">33241760</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy SW, Seedat F, Kearins O, Press M, Walton J, Myles J, et al. . The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation. Br J Cancer. 2022;126(9):1355–61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8808468</ArticleId><ArticleId IdType="pubmed">35110696</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentscher KE, Zhou X, Small BJ, Cohen HJ, Dilawari AA, Patel SK, et al. . Loneliness and mental health during the COVID-19 pandemic in older breast cancer survivors and noncancer controls. Cancer. 2021;127(19):3671–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8419003</ArticleId><ArticleId IdType="pubmed">34161601</ArticleId></ArticleIdList></Reference><Reference><Citation>Turgeman I, Goshen-Lago T, Waldhorn I, Karov K, Groisman L, Reiner Benaim A, et al. . Psychosocial perspectives among cancer patients during the coronavirus disease 2019 (COVID-19) crisis: an observational longitudinal study. Cancer Rep. 2022;5(5):e1506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420321</ArticleId><ArticleId IdType="pubmed">34405968</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah DA, Sall D, Peng W, Sharer R, Essary AC, Radhakrishnan P. Exploring the role of telehealth in providing equitable healthcare to the vulnerable patient population during COVID-19. J Telemed Telecare. 2022:1357633X2211137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9283958</ArticleId><ArticleId IdType="pubmed">35833345</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab M, Rosenblatt E, Prajogi B, Zubizarretta E, Mikhail M. Opportunities in telemedicine, lessons learned after COVID-19 and the way into the future. Int J Radiat Oncol Biol Phys. 2020;108(2):438–43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462967</ArticleId><ArticleId IdType="pubmed">32890528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolluri S, Stead TS, Mangal RK, Coffee RL Jr, Littell J, Ganti L. Telehealth in response to the rural health disparity. Health Psychol Res. 2022;10(3):37445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9392842</ArticleId><ArticleId IdType="pubmed">35999970</ArticleId></ArticleIdList></Reference><Reference><Citation>
McKinsey&amp;Company, “How COVID-19 has companies over the technology tipping point: and transformed business forever”. 2020. [Online]. Available from: https://www.mckinsey.com/∼/media/McKinsey/Business%20Functions/Strategy%20and%20Corporate%20Finance/Our%20Insights/How%20COVID%2019%20has%20pushed%20companies%20over%20the%20technology%20tipping%20point%20and%20transformed%20business%20forever/How-COVID-19-has-pushed-companies-over-the%20technology%20tipping-point-final.pdf</Citation></Reference><Reference><Citation>Garavand A, Khodaveisi T, Aslani N, Hosseiniravandi M, Shams R, Behmanesh A. Telemedicine in cancer care during COVID-19 pandemic: a systematic mapping study. Health Technol. 2023;13(4):665–78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10256577</ArticleId><ArticleId IdType="pubmed">37363344</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wang L. “Telehealth-based cancer care surged during COVID. Will it continue?” NIH. 2022. [Online]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2022/pandemic-telehealth-surge-cancer-care</Citation></Reference><Reference><Citation>Paige SR, Campbell-Salome G, Alpert J, Markham MJ, Murphy M, Heffron E, et al. . Cancer patients’ satisfaction with telehealth during the COVID-19 pandemic. PLoS One. 2022;17(6):e0268913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9165798</ArticleId><ArticleId IdType="pubmed">35657778</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocco N, Montagna G, Di Micco R, Benson J, Criscitiello C, Chen L, et al. . The impact of the COVID-19 pandemic on surgical management of breast cancer: global trends and future perspectives. Oncologist. 2021;26(1):e66–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675306</ArticleId><ArticleId IdType="pubmed">33044007</ArticleId></ArticleIdList></Reference><Reference><Citation>Petropoulou Z, Arkadopoulos N, Michalopoulos NV. Breast cancer and COVID-19: challenges in surgical management. Cancers. 2022;14(21):5360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9653580</ArticleId><ArticleId IdType="pubmed">36358779</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers C, Bennett K, Cahir C. Lessons learned from COVID-19: improving breast cancer care post-pandemic from the patient perspective. Support Care Cancer. 2024;32(6):338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11087304</ArticleId><ArticleId IdType="pubmed">38730019</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrowder DA, Miller FG, Vaz K, Anderson Cross M, Anderson-Jackson L, Bryan S, et al. . The utilization and benefits of telehealth services by health care professionals managing breast cancer patients during the COVID-19 pandemic. Healthcare. 2021;9(10):1401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8535379</ArticleId><ArticleId IdType="pubmed">34683081</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>